In this episode, Thomas Fuchs, Chief AI Officer at Eli Lilly, shares his journey from early machine learning research to spearheading transformative AI initiatives across the pharmaceutical value chain. Lilly is running over a thousand AI projects—from drug discovery and development to manufacturing and commercial operations—leveraging innovations like language models for chatbots, computer vision for quality control, and biomarker development.
Thomas emphasizes trust, transparency, and collaboration as critical to AI adoption, supported by AI certification programs for all Lilly technology employees, as well as AI education resources being made available for everyone at Lilly. He also highlights the company’s unique “lab-in-the-loop” setups that generate synthetic data to accelerate innovation.
Thomas shares real-world successes, including AI-assisted drug discovery and intelligent chatbots, and how AI is building confidence across the organization. With robust data infrastructure and scalable strategies for synthesizing large datasets, Lilly is driving rapid innovation. Thomas predicts faster drug design, broader access to medicines, and continuous education as defining trends for AI in healthcare. Take a listen.
In this episode, Manu Tandon discusses how Beth Israel Deaconess Medical Center, a Harvard Medical School-affiliated academic medical center, is working towards their mission...
In this episode, Mudit Garg discusses the evolution of Qventus and how they are applying AI to help hospitals and health systems in managing...
In this episode, John Donohue, Vice President of Entity Services at Penn Medicine talks about their 6-years long, $1.5 billion investment in a hospital...
